

## **Perrigo Announces FDA Final Approval For Generic Equivalent To Cutivate® Lotion, 0.05%**

ALLEGAN, Mich., July 31, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received final approval for its abbreviated new drug application for fluticasone propionate lotion, 0.05%, the generic equivalent to Cutivate® Lotion, 0.05%. Perrigo will commence shipment of the product immediately.

(Logo: <http://photos.prnewswire.com/prnh/20120301/DE62255LOGO> )

Cutivate® Lotion 0.05% (fluticasone propionate lotion, 0.05%) is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 1 year of age or older and has annual sales of approximately \$19 million, as measured by Symphony Health Solutions.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture topicals, lotions and foams. We are excited to market this product and are dedicated to making quality healthcare more affordable for all consumers around the globe."

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (<http://www.perrigo.com>).

*Note:* Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any

forward-looking statements, whether as a result of new information, future events or otherwise.

## SOURCE Perrigo Company

For further information: Arthur J. Shannon, Vice President, Investor Relations and Communication, (269) 686-1709, E-mail: [ajshannon@perrigo.com](mailto:ajshannon@perrigo.com); Bradley Joseph, Senior Manager, Investor Relations and Communication, (269) 686-3373, E-mail: [bradley.joseph@perrigo.com](mailto:bradley.joseph@perrigo.com)

---

<https://investor.perrigo.com/2013-07-31-Perrigo-Announces-FDA-Final-Approval-For-Generic-Equivalent-To-Cutivate-Lotion-0-05>